Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
-
New drug ERAS-0015 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called ERAS-0015 in people with advanced solid tumors that have certain RAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 200 adults will participate. This is not a cur…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 26, 2026 04:56 UTC
-
New hope for Hard-to-Treat cancers: first human trial of ERAS-4001 begins
Disease control Recruiting nowThis early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 200 participants will take part to help find …
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC